Ronit Simantov MD

Ronit Simantov MD General Information

Biography

Dr. Ronit Simantov serves as Chief Medical and Chief Scientific Officer at Gamida Cell. Prior to joining Gamida Cell, Dr. Simantov served as vice president, Oncology Global Medical Affairs between January 2014 and June 2017 and as US Medical Affair Lead, Oncology Business Unit between September 2011 and December 2013 for Pfizer Inc. Prior to that, Dr. Simantov served as vice president of clinical research oncology for OSI Pharmaceuticals and as Chief Medical Officer for CuraGen Corporation (acquired by Celldex) where she led development of small molecules and antibody drug conjugates. Dr. Simantov serves on the board of directors of Tempest Therapeutics, Inc. and Clovis Oncology. Prior to joining industry, Dr. Simantov spent seven years on the academic faculty at Weill Medical College of Cornell University, where she directed the fellowship program and conducted angiogenesis and vascular biology research. Dr. Simantov has authored over 40 peer-reviewed manuscripts. Dr. Simantov holds an M.D. from New York University School of Medicine and a B.A. from Johns Hopkins University. Dr. Simantov completed a residency in internal medicine at New York Hospital Cornell Medical Center, and a fellowship in hematology and oncology at Weill Cornell Medicine.